120 related articles for article (PubMed ID: 38153295)
1. Discovery of Novel Inhibitors of BRD4 for Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design.
Zhong H; Wang X; Chen S; Wang Z; Wang H; Xu L; Hou T; Yao X; Li D; Pan P
J Med Chem; 2024 Jan; 67(1):138-151. PubMed ID: 38153295
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer.
Jiang W; Wang X; Shu C; Hou Q; Yang K; Wu X
Bioorg Chem; 2022 Feb; 119():105575. PubMed ID: 34995979
[TBL] [Abstract][Full Text] [Related]
3. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
4. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
5. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
6. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
[TBL] [Abstract][Full Text] [Related]
7. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
Blee AM; Liu S; Wang L; Huang H
Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors.
Xu KY; Wang XT; Cheng L; Cui QH; Shi JT; Zhang LW; Chen SW
Bioorg Med Chem; 2023 Jan; 78():117152. PubMed ID: 36599264
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Insights into the Selective Dual BET and PLK1 Inhibitory Activity of a Novel Benzamide Compound in Castration-Resistant Prostrate Cancer.
Akawa OB; Subair TI; Omolabi KF; Okunlola FO; Soliman MES
Chem Biodivers; 2021 Dec; 18(12):e2100519. PubMed ID: 34729902
[TBL] [Abstract][Full Text] [Related]
10. Importance of a crystalline water network in docking-based virtual screening: a case study of BRD4.
Zhong H; Wang Z; Wang X; Liu H; Li D; Liu H; Yao X; Hou T
Phys Chem Chem Phys; 2019 Dec; 21(45):25276-25289. PubMed ID: 31701109
[TBL] [Abstract][Full Text] [Related]
11. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
Tumdam R; Kumar A; Subbarao N; Balaji BS
SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
Liang D; Yu Y; Ma Z
Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
[TBL] [Abstract][Full Text] [Related]
15. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
16. Y06014 is a selective BET inhibitor for the treatment of prostate cancer.
Wu TB; Xiang QP; Wang C; Wu C; Zhang C; Zhang MF; Liu ZX; Zhang Y; Xiao LJ; Xu Y
Acta Pharmacol Sin; 2021 Dec; 42(12):2120-2131. PubMed ID: 33654218
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
Zhang M; Zhang Y; Song M; Xue X; Wang J; Wang C; Zhang C; Li C; Xiang Q; Zou L; Wu X; Wu C; Dong B; Xue W; Zhou Y; Chen H; Wu D; Ding K; Xu Y
J Med Chem; 2018 Apr; 61(7):3037-3058. PubMed ID: 29566488
[TBL] [Abstract][Full Text] [Related]
20. Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
Xing J; Zhang R; Jiang X; Hu T; Wang X; Qiao G; Wang J; Yang F; Luo X; Chen K; Shen J; Luo C; Jiang H; Zheng M
Eur J Med Chem; 2019 Feb; 163():281-294. PubMed ID: 30529546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
